- cafead Feb 24, 2023 at 09:12: AM
via In the midst of Amarin’s activist investor blowout with Sarissa Capital Management, the company has a new battle brewing.
In a new antitrust suit, generics maker Hikma has accused Amarin of “deliberately and meticulously” locking up the supply icosapent ethyl in an attempt to block generic competition. Icosapent ethyl is the active ingredient in Amarin's only drug, Vascepa.
article source
In a new antitrust suit, generics maker Hikma has accused Amarin of “deliberately and meticulously” locking up the supply icosapent ethyl in an attempt to block generic competition. Icosapent ethyl is the active ingredient in Amarin's only drug, Vascepa.
article source